Didn't Make it to ADA 2017?

Watch our poster presentations and download our posters now!

1820-P: The Depletion of Peripheral NK Cells and NK T Lymphocytes in a Spontaneously Diabetic Non-Human Primate Model

1881-P: Rhythmic Differences of Blood Glucose Circadian between Normoglycemic and Diabetic Non-Human Primates

WEBINAR: Are You Choosing the Right Model?

A Guide to Selecting Your Next Immuno-Oncology Model

Thursday, June 22, 2017 @ 11am EDT | 4pm BST | 5pm CEST

Join our webinar to discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct model for your studies. Learn how current models are being used to progress combination regimens, including dual immunotherapies, and I/O agents plus other treatment modalities.

NEW WHITE PAPER: Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

ON-DEMAND WEBINAR: Translational Platforms to Model Pre-Diabetes, Diabetes, and Complications

Join our webinar to discover the development and utility of CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications. Learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.

Didn't Make it to AACR 2017?

Read and download all of our 14 posters now!

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

June 15, 2017

Why the Current Excitement over Krill in CVD?

Krill are small crustaceans found in all the world's oceans, which have been harvested as a human and animal food source for many years, recently for use in dietary supplements. A new collaborative study has demonstrated that a novel long-chain (LC) omega-3 rich phospholipid preparation extracted from krill oil can reduce...

Read More

June 15, 2017

Why the Current Excitement over Krill in CVD?

Krill are small crustaceans found in all the world's oceans, which have been harvested as a...

Read More

June 13, 2017

Breast Cancer PDX Models

Patient-derived xenograft (PDX) models enhance predictability in oncology preclinical studies....

Read More

June 8, 2017

First Cancer Drug Approval Based on Biomarkers, not Tumor Location

For the first time in their history, the U.S. Food and Drug Administration has approved a cancer...

Read More

June 6, 2017

PCSK9 Inhibitor Data in Diabetic Patients to be Highlighted at ADA 2017

Recent years have witnessed a change in cholesterol-lowering compounds - from your parents’...

Read More

June 1, 2017

The Translatable Value of Spontaneously Obese Rhesus for New Insulin-Sensitizing Therapeutics

There's a critical need for novel treatment options to ameliorate insulin resistance,...

Read More

Upcoming Events


June 2 - 6, 2017

ASCO 2017 Annual Meeting

Booth #17017

https://am.asco.org/


June 9 - 13, 2017

American Diabetes Association

San Diego, CA - Booth #131

www.professional.diabetes.org/


June 17 - 18, 2017

SAPA New England

Cambridge, MA

www.sapa-neweb.org


June 21, 2017

Symposium: Oncology Drug Discovery, Translating from Target to Patient

Terrass Hotel - Paris, France

Register


June 23 - 24, 2017

SAPA-GP Annual Conference

Sheraton Valley Forge Hotel, PA 

www.sapa-gp.org


June 28 - July 2, 2017

Bio Taiwan

Taipei Taiwan (Booth #N202)

www.bio-taiwan.com


July 2, 2017

Israeli Immunology Society Symposium

Hebrew University, Jerusalem

www.iis.org.il


July 3, 2017

CrownBio University: Lunch & Learn Series

Tel Aviv, Israel


July 16 - 20, 2017

Molecular Therapeutics of Cancer Research Conference

Burlington, VT

www.cancermoleculartherapeutics.org


July 18, 2017

From Bench to Bedside

Burlington, Vermont


July 18 - 20, 2017

Tumor Models Boston

The Colonnade Hotel, Boston, MA

www.tumor-models.com


September 6 - 9, 2017

Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Mainz/Frankfurt, Germany

www.cancerimmunotherapyconference.org


September 15, 2017

Crown Bioscience Symposium

San Diego, CA


September 21, 2017

Crown Bioscience Diabetes Symposium

Boston, MA


September 29 - 30, 2017

25th Annual SAPA Conference

New Jersey

www.sapaweb.org